ArticleCost effectiveness and resource allocation : C/E2009

Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective.

Werner A Scherbaum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.